Collectively, increased MET and AKT was correlated with rituximab resistance of DLBCL, which was consistent with our results that the phosphorylation level of AKT was elevated upon lncRNA CHROMR overexpression. This evidence concerns the gene CHROMR and diffuse large B-cell lymphoma.